COLL - コレギウム・ファ―マシュ―ティカル (Collegium Pharmaceutical Inc.) コレギウム・ファ―マシュ―ティカル

 COLLのチャート


 COLLの企業情報

symbol COLL
会社名 Collegium Pharmaceuticals Inc (コレギウム・ファ―マシュ―ティカル)
分野(sector) Health Care   ヘルスケア
産業(industry) Major Pharmaceuticals  
業種 医薬品   医療関連(Health Care)
概要 事業概要 コレギウム・ファーマシューティカル(Collegium Pharmaceutical Inc.)は特殊医薬品会社である。同社は、慢性疼痛及びその他疾患の治療用「DETERx」プラットフォーム技術を組み込んだ乱用防止製品の開発・製品化を行う。同社の製品はXtampza ERとONSOLISを含む。DETERxプラットフォームは、鎮痛、咀嚼、加熱および注射を含む一般的な乱用と改ざんの方法に対して保護しながら、徐放性ドラッグデリバリーを提供する。Xtampza ERは、一般的な乱用と偶発的な誤用を受けた後、徐放性薬物放出プロファイルを維持しながら、適切な疼痛管理を提供するように設計された。ONSOLISは、永続的な癌の痛みのために既にオピオイド療法を受けて耐性がある18歳以上のがん患者(BTPc)における突破痛の管理を目的とする経粘膜即時放出フェンタニル(TIRF)フィルムである。   コレギウム・ファ―マシュ―ティカルは米国の製薬会社。慢性疼痛および他の疾患の治療用に開発された特許取得済みプラットフォ―ム技術「DETERx」を組み込んだ、次世代の医薬品の開発、製品化を手掛ける。開発中の医薬品に「Xtampza ER」や「Xtampza」がある。   Collegium Pharmaceutical, Inc. operates as a pharmaceutical company, which engages in the developing and planning to commercialize next generation, abuse-deterrent products for the treatment of patients suffering from chronic pain and other diseases. Its products include Xtampza ER, Nucynta ER and Nucynta IR. The Xtampza ER provides pain control while maintaining its extended-release drug release profile after being subjected to common methods of abuse and accidental misuse. The Nucynta ER for the treatment of chronic pain and neuropathic pain associated with diabetic peripheral neuropathy. The Nucynta is a release formulation of tapentadol indicated for the management of acute pain severe enough to require an opioid analgesic. The company was founded by Michael Thomas Heffernan in October 2003 and is headquartered in Stoughton, MA.
本社所在地 780 Dedham Street Suite 800 Canton MA 02021 USA
代表者氏名 Michael Thomas Heffernan マイケル・トーマス・ヘファナン
代表者役職名 Chairman of the Board President 取締役会長会長
電話番号 +1 781-713-3699
設立年月日 37347
市場名 NASDAQ National Market System
ipoyear 2015年
従業員数 250人
url www.collegiumpharma.com
nasdaq_url https://www.nasdaq.com/symbol/coll
adr_tso
EBITDA EBITDA(百万ドル) 11.26000
終値(lastsale) 16.98
時価総額(marketcap) 564104533.92
時価総額 時価総額(百万ドル) 571.41330
売上高 売上高(百万ドル) 159.55400
企業価値(EV) 企業価値(EV)(百万ドル) 449.16630
当期純利益 当期純利益(百万ドル) -62.37800
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 Collegium Pharmaceutical Inc revenues increased from $5.7M to $136.8M. Net loss decreased 28% to $31.7M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Lower net loss reflects Interest Income increase from $235K to $646K (income) Research and Development decrease of 1% to $3.8M (expense).

 COLLのテクニカル分析


 COLLのニュース

   The Daily Biotech Pulse: Positive Data Readouts To Spur Aclaris, Moderna And Ultragenyx  2020/01/10 12:13:12 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week highs on Jan. 9) Acceleron Pharma Inc (NASDAQ: XLRN ) Allergan plc (NYSE: AGN ) Applied Genetic Technologies Corp (NASDAQ: AGTC ) ( announced positive midstage results for its gene therapy to treat inherited eye disorder) Applied Therapeutics Inc (NASDAQ: APLT ) Bio-Rad Laboratories, Inc. (NYSE: BIO ) Bristol-Myers Squibb Co (NYSE: BMY ) Collegium Pharmaceutical Inc (NASDAQ: COLL ) COLLPLANT BIOTE/S ADR (NASDAQ: CLGN ) DBV TECHNOLOGIE/S ADR (NASDAQ: DBVT ) (reported positive results for a late-stage study of its peanut allergy patch) DexCom, Inc. (NASDAQ: DXCM ) Global Blood Therapeutics Inc (NASDAQ: GBT ) Grifols SA - ADR ADR Class B (NASDAQ: GRFS ) Inspire Medical Systems Inc (NYSE: INSP ) ITAMAR MED LTD/S ADR (NASDAQ: ITMR ) Karyopharm Therapeutics Inc (NASDAQ: KPTI ) LeMaitre Vascular Inc (NASDAQ: LMAT ) Masimo Corporation (NASDAQ: MASI ) Medtronic PLC (NYSE: MDT )(announced the acquisition of Stimgenics) Molecular Templates Inc (NASDAQ: MTEM ) Morphosys Ag (NASDAQ: MOR ) NuVasive, Inc.
   The Daily Biotech Pulse: Merck's Keytruda Snags Another FDA Approval, DBV Announces Positive Peanut Allergy Study Findings, Applied Genetic Soars On Trial Results  2020/01/09 13:39:54 Benzinga
The following is a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks that hit 52-week highs on Jan. 8.) Allergan plc (NYSE: AGN ): AbbVie Inc (NYSE: ABBV ) announced plans to integrate Allergan, which it has agreed to acquire Applied Therapeutics Inc (NASDAQ: APLT ) ( announced positive results for the midstage study of its experimental drug to treat inherited galactose processing disorder) Collegium Pharmaceutical Inc (NASDAQ: COLL ) (announced upbeat guidance for fiscal year 2020) Bio-Rad Laboratories, Inc. Class A (NYSE: BIO ) Dermira Inc (NASDAQ: DERM ) DexCom, Inc. (NASDAQ: DXCM ) Grifols SA - ADR ADR Class B (NASDAQ: GRFS ) Inspire Medical Systems Inc (NYSE: INSP ) Medtronic PLC (NYSE: MDT ) Nevro Corp (NYSE: NVRO ) NuVasive, Inc. (NASDAQ: NUVA ) (SunTrust initiated coverage of the stock with a Buy rating) PTC Therapeutics, Inc. (NASDAQ: PTCT ) Syneos Health Inc (NASDAQ: SYNH ) TG Therapeutics Inc (NASDAQ: TGTX ) Turning Point Therapeutics Inc (NASDAQ: TPTX ) Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX ) Zoetis Inc (NYSE: ZTS ) None of the NYSE- or Nasdaq-listed biotech hit 52-week lows Wednesday.
   The Daily Biotech Pulse: Tonix Says No Surprises In FDA Meeting Minutes, Aravive Offering, FDA Nod For Qiagen  2019/11/27 12:26:05 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Nov. 26) Allakos Inc (NASDAQ: ALLK ) Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY ) Ardelyx Inc (NASDAQ: ARDX ) ( announced a research collaboration with Japan's Kyowa Kirin and an investment in the company by the latter) Arrowhead Pharmaceuticals Inc (NASDAQ: ARWR )(reacted to its full-year results) Avadel Pharmaceuticals PLC (NASDAQ: AVDL ) Axsome Therapeutics Inc (NASDAQ: AXSM ) Bio-Rad Laboratories, Inc. (NYSE: BIO ) BIO-TECHNE Corp (NASDAQ: TECH ) ChemoCentryx Inc (NASDAQ: CCXI )( announced positive late-stage results for rare inflammation disease drug) Collegium Pharmaceutical Inc (NASDAQ: COLL ) Cue Biopharma Inc (NASDAQ: CUE ) DexCom, Inc. (NASDAQ: DXCM ) ESSA Pharma Inc (NASDAQ: EPIX ) Flexion Therapeutics Inc (NASDAQ: FLXN ) Global Blood Therapeutics Inc (NASDAQ: GBT )(announced FDA nod for sickle cell disease drug) Grifols SA - ADR ADR Class B (NASDAQ: GRFS ) Globus Medical Inc (NYSE: GMED ) Horizon Therapeutics PLC (NASDAQ: HZNP ) Insulet Corporation (NASDAQ: PODD ) Krystal Biotech Inc (NASDAQ: KRYS ) Merck & Co., Inc. (NYSE: MRK )(Keytruda was approved in China as a first-line treatment for lung cancer, in combination with chemotherapy) Molecular Templates Inc (NASDAQ: …
   The Daily Biotech Pulse: ChemoCentryx Triples On Data Readout, Global Blood Given FDA Nod, Positive Safety Review For Genfit's NASH Drug  2019/11/26 13:06:41 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks that hit 52-week highs on Nov. 25.) ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD ) Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY ) Amgen, Inc. (NASDAQ: AMGN ) Antares Pharma Inc (NASDAQ: ATRS ) Arrowhead Pharmaceuticals Inc (NASDAQ: ARWR ) Arvinas Inc (NASDAQ: ARVN ) (Guggenheim initiated coverage of stock with Buy rating and $50 price target) Avadel Pharmaceuticals PLC (NASDAQ: AVDL ) (announced achievement of enrollment target in a Phase 3 trial of drug to treat excessive daytime sleepiness and cataplexy in patients with narcolepsy) Axsome Therapeutics Inc (NASDAQ: AXSM ) Beigene Ltd (NASDAQ: BGNE ) Bio-Rad Laboratories, Inc. Class A (NYSE: BIO ) BIO-TECHNE Corp (NASDAQ: TECH ) BioNTech SE – ADR (NASDAQ: BNTX ) Collegium Pharmaceutical Inc (NASDAQ: COLL ) Cue Biopharma Inc (NASDAQ: CUE ) DexCom, Inc. (NASDAQ: DXCM ) Dicerna Pharmaceuticals Inc (NASDAQ: DRNA ) Epizyme Inc (NASDAQ: EPZM ) ESSA Pharma Inc (NASDAQ: EPIX ) Flexion Therapeutics Inc (NASDAQ: FLXN ) GENMAB A/S/S ADR (NASDAQ: GMAB ) Globus Medical Inc (NYSE: GMED ) Halozyme Therapeutics, Inc.
   The Daily Biotech Pulse: Therapix Calls Off Merger, Alimera's Reverse Split, 2 Biotechs To Debut  2019/11/08 13:14:09 Benzinga
The following is a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks that hit 52-week highs Nov. 7.) Collegium Pharmaceutical Inc (NASDAQ: COLL ) (reacted to third-quarter results released after the market close Wednesday) Deciphera Pharmaceuticals Inc (NASDAQ: DCPH ) DexCom, Inc. (NASDAQ: DXCM ) (reacted to its better-than-expected third-quarter results ) INNATE PHARMA S/S ADR (NASDAQ: IPHA ) Rapt Therapeutics Inc (NASDAQ: RAPT ) (went public Oct. 31) Viela Bio Inc (NASDAQ: VIE ) (went public Oct. 3) XOMA Corp (NASDAQ: XOMA ) Down In The Dumps (Biotech stocks that hit 52-week lows Nov. 7.) Allena Pharmaceuticals Inc (NASDAQ: ALNA ) (reported positive results from two studies evaluating its reloxaliase in high-risk patients with enteric hyperoxaluria and advanced chronic kidney disease) Auris Medical Holding Ltd (NASDAQ: EARS ) bluebird bio Inc (NASDAQ: BLUE ) Caladrius Biosciences Inc (NASDAQ: CLBS ) (reacted to its third-quarter results) CENTOGENE ORD (NASDAQ: CNTG ) (went public Thursday) Cocrystal Pharma Inc (NASDAQ: COCP ) Corbus Pharmaceuticals Holdings Inc (NASDAQ: CRBP ) Helius Medical Technologies Inc (NASDAQ: HSDT ) Infinity Pharmaceuticals Inc.
   The Daily Biotech Pulse: Tonix Says No Surprises In FDA Meeting Minutes, Aravive Offering, FDA Nod For Qiagen  2019/11/27 12:26:05 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Nov. 26) Allakos Inc (NASDAQ: ALLK ) Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY ) Ardelyx Inc (NASDAQ: ARDX ) ( announced a research collaboration with Japan's Kyowa Kirin and an investment in the company by the latter) Arrowhead Pharmaceuticals Inc (NASDAQ: ARWR )(reacted to its full-year results) Avadel Pharmaceuticals PLC (NASDAQ: AVDL ) Axsome Therapeutics Inc (NASDAQ: AXSM ) Bio-Rad Laboratories, Inc. (NYSE: BIO ) BIO-TECHNE Corp (NASDAQ: TECH ) ChemoCentryx Inc (NASDAQ: CCXI )( announced positive late-stage results for rare inflammation disease drug) Collegium Pharmaceutical Inc (NASDAQ: COLL ) Cue Biopharma Inc (NASDAQ: CUE ) DexCom, Inc. (NASDAQ: DXCM ) ESSA Pharma Inc (NASDAQ: EPIX ) Flexion Therapeutics Inc (NASDAQ: FLXN ) Global Blood Therapeutics Inc (NASDAQ: GBT )(announced FDA nod for sickle cell disease drug) Grifols SA - ADR ADR Class B (NASDAQ: GRFS ) Globus Medical Inc (NYSE: GMED ) Horizon Therapeutics PLC (NASDAQ: HZNP ) Insulet Corporation (NASDAQ: PODD ) Krystal Biotech Inc (NASDAQ: KRYS ) Merck & Co., Inc. (NYSE: MRK )(Keytruda was approved in China as a first-line treatment for lung cancer, in combination with chemotherapy) Molecular Templates Inc (NASDAQ: …
   The Daily Biotech Pulse: ChemoCentryx Triples On Data Readout, Global Blood Given FDA Nod, Positive Safety Review For Genfit's NASH Drug  2019/11/26 13:06:41 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks that hit 52-week highs on Nov. 25.) ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD ) Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY ) Amgen, Inc. (NASDAQ: AMGN ) Antares Pharma Inc (NASDAQ: ATRS ) Arrowhead Pharmaceuticals Inc (NASDAQ: ARWR ) Arvinas Inc (NASDAQ: ARVN ) (Guggenheim initiated coverage of stock with Buy rating and $50 price target) Avadel Pharmaceuticals PLC (NASDAQ: AVDL ) (announced achievement of enrollment target in a Phase 3 trial of drug to treat excessive daytime sleepiness and cataplexy in patients with narcolepsy) Axsome Therapeutics Inc (NASDAQ: AXSM ) Beigene Ltd (NASDAQ: BGNE ) Bio-Rad Laboratories, Inc. Class A (NYSE: BIO ) BIO-TECHNE Corp (NASDAQ: TECH ) BioNTech SE – ADR (NASDAQ: BNTX ) Collegium Pharmaceutical Inc (NASDAQ: COLL ) Cue Biopharma Inc (NASDAQ: CUE ) DexCom, Inc. (NASDAQ: DXCM ) Dicerna Pharmaceuticals Inc (NASDAQ: DRNA ) Epizyme Inc (NASDAQ: EPZM ) ESSA Pharma Inc (NASDAQ: EPIX ) Flexion Therapeutics Inc (NASDAQ: FLXN ) GENMAB A/S/S ADR (NASDAQ: GMAB ) Globus Medical Inc (NYSE: GMED ) Halozyme Therapeutics, Inc.
   The Daily Biotech Pulse: Therapix Calls Off Merger, Alimera's Reverse Split, 2 Biotechs To Debut  2019/11/08 13:14:09 Benzinga
The following is a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks that hit 52-week highs Nov. 7.) Collegium Pharmaceutical Inc (NASDAQ: COLL ) (reacted to third-quarter results released after the market close Wednesday) Deciphera Pharmaceuticals Inc (NASDAQ: DCPH ) DexCom, Inc. (NASDAQ: DXCM ) (reacted to its better-than-expected third-quarter results ) INNATE PHARMA S/S ADR (NASDAQ: IPHA ) Rapt Therapeutics Inc (NASDAQ: RAPT ) (went public Oct. 31) Viela Bio Inc (NASDAQ: VIE ) (went public Oct. 3) XOMA Corp (NASDAQ: XOMA ) Down In The Dumps (Biotech stocks that hit 52-week lows Nov. 7.) Allena Pharmaceuticals Inc (NASDAQ: ALNA ) (reported positive results from two studies evaluating its reloxaliase in high-risk patients with enteric hyperoxaluria and advanced chronic kidney disease) Auris Medical Holding Ltd (NASDAQ: EARS ) bluebird bio Inc (NASDAQ: BLUE ) Caladrius Biosciences Inc (NASDAQ: CLBS ) (reacted to its third-quarter results) CENTOGENE ORD (NASDAQ: CNTG ) (went public Thursday) Cocrystal Pharma Inc (NASDAQ: COCP ) Corbus Pharmaceuticals Holdings Inc (NASDAQ: CRBP ) Helius Medical Technologies Inc (NASDAQ: HSDT ) Infinity Pharmaceuticals Inc.
   Collegium Pharmaceutical (COLL) Q2 Earnings Surpass Estimates  2019/08/07 22:35:06 Zacks Investment Research
Collegium Pharmaceutical (COLL) delivered earnings and revenue surprises of 152.63% and -1.31%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
   Earnings Preview: Collegium Pharmaceutical (COLL) Q2 Earnings Expected to Decline  2019/07/31 14:36:33 Zacks Investment Research
Collegium Pharmaceutical (COLL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
  デイリーバイオテクノロジーパルス:トニックスは、FDAの会議議事録、Aravive Offering、Fia Nod for Qiagenに驚きはないと言います」 The Daily Biotech Pulse: Tonix Says No Surprises In FDA Meeting Minutes, Aravive Offering, FDA Nod For Qiagen  2019/11/27 12:26:05 Benzinga
「過去24時間にわたるバイオテクノロジー分野の主要な開発の概要をご紹介します。スケーリング(11月26日、52週間ぶりの高値に達するバイオテック株)Allakos Inc(NASDAQ:ALLK)Alnylam Pharmaceuticals、Inc.(NASDAQ:ALNY) Ardelyx Inc(NASDAQ:ARDX)(日本の協和キリンとの共同研究および同社による同社への投資を発表)Arrowhead Pharmaceuticals Inc(NASDAQ:ARWR)(通年の結果に反応)Avadel Pharmaceuticals PLC(NASDAQ:AVDL )Axsome Therapeutics Inc(NASDAQ:AXSM)Bio-Rad Laboratories、Inc.(NYSE:BIO)BIO-TECHNE Corp(NASDAQ:TECH)ChemoCentryx Inc(NASDAQ:CCXI)(まれな炎症性疾患治療薬の陽性後期結果を発表) Collegium Pharmaceutical Inc(NASDAQ:COLL)Cue Biopharma Inc(NASDAQ:CUE)DexCom、Inc.(NASDAQ:DXCM)ESSA Pharma Inc(NASDAQ:EPIX)Flexion Therapeutics Inc(NASDAQ:FLXN)Global Blood Therapeutics Inc(NASDAQ:GBT) (鎌状赤血球症薬のFDA承認を発表)Grifols SA-ADR ADRクラスB(NASDAQ:GRFS)Globus Medical Inc(NYSE:GMED)Horizon Therapeutics PLC(NASDAQ:HZNP)Insulet Corporation(NASDAQ:PODD)Krystal Biotech Inc(NASDAQ:KRYS)Merck&Co.、Inc.(NYSE:MRK) (Keytrudaは、化学療法と組み合わせた肺癌の第一選択治療薬として中国で承認されました)Molecular Templates Inc(NASDAQ:…
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Nov. 26) Allakos Inc (NASDAQ: ALLK ) Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY ) Ardelyx Inc (NASDAQ: ARDX ) ( announced a research collaboration with Japan's Kyowa Kirin and an investment in the company by the latter) Arrowhead Pharmaceuticals Inc (NASDAQ: ARWR )(reacted to its full-year results) Avadel Pharmaceuticals PLC (NASDAQ: AVDL ) Axsome Therapeutics Inc (NASDAQ: AXSM ) Bio-Rad Laboratories, Inc. (NYSE: BIO ) BIO-TECHNE Corp (NASDAQ: TECH ) ChemoCentryx Inc (NASDAQ: CCXI )( announced positive late-stage results for rare inflammation disease drug) Collegium Pharmaceutical Inc (NASDAQ: COLL ) Cue Biopharma Inc (NASDAQ: CUE ) DexCom, Inc. (NASDAQ: DXCM ) ESSA Pharma Inc (NASDAQ: EPIX ) Flexion Therapeutics Inc (NASDAQ: FLXN ) Global Blood Therapeutics Inc (NASDAQ: GBT )(announced FDA nod for sickle cell disease drug) Grifols SA - ADR ADR Class B (NASDAQ: GRFS ) Globus Medical Inc (NYSE: GMED ) Horizon Therapeutics PLC (NASDAQ: HZNP ) Insulet Corporation (NASDAQ: PODD ) Krystal Biotech Inc (NASDAQ: KRYS ) Merck & Co., Inc. (NYSE: MRK )(Keytruda was approved in China as a first-line treatment for lung cancer, in combination with chemotherapy) Molecular Templates Inc (NASDAQ: …
   The Daily Biotech Pulse: ChemoCentryx Triples On Data Readout, Global Blood Given FDA Nod, Positive Safety Review For Genfit's NASH Drug  2019/11/26 13:06:41 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks that hit 52-week highs on Nov. 25.) ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD ) Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY ) Amgen, Inc. (NASDAQ: AMGN ) Antares Pharma Inc (NASDAQ: ATRS ) Arrowhead Pharmaceuticals Inc (NASDAQ: ARWR ) Arvinas Inc (NASDAQ: ARVN ) (Guggenheim initiated coverage of stock with Buy rating and $50 price target) Avadel Pharmaceuticals PLC (NASDAQ: AVDL ) (announced achievement of enrollment target in a Phase 3 trial of drug to treat excessive daytime sleepiness and cataplexy in patients with narcolepsy) Axsome Therapeutics Inc (NASDAQ: AXSM ) Beigene Ltd (NASDAQ: BGNE ) Bio-Rad Laboratories, Inc. Class A (NYSE: BIO ) BIO-TECHNE Corp (NASDAQ: TECH ) BioNTech SE – ADR (NASDAQ: BNTX ) Collegium Pharmaceutical Inc (NASDAQ: COLL ) Cue Biopharma Inc (NASDAQ: CUE ) DexCom, Inc. (NASDAQ: DXCM ) Dicerna Pharmaceuticals Inc (NASDAQ: DRNA ) Epizyme Inc (NASDAQ: EPZM ) ESSA Pharma Inc (NASDAQ: EPIX ) Flexion Therapeutics Inc (NASDAQ: FLXN ) GENMAB A/S/S ADR (NASDAQ: GMAB ) Globus Medical Inc (NYSE: GMED ) Halozyme Therapeutics, Inc.
   The Daily Biotech Pulse: Therapix Calls Off Merger, Alimera's Reverse Split, 2 Biotechs To Debut  2019/11/08 13:14:09 Benzinga
The following is a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks that hit 52-week highs Nov. 7.) Collegium Pharmaceutical Inc (NASDAQ: COLL ) (reacted to third-quarter results released after the market close Wednesday) Deciphera Pharmaceuticals Inc (NASDAQ: DCPH ) DexCom, Inc. (NASDAQ: DXCM ) (reacted to its better-than-expected third-quarter results ) INNATE PHARMA S/S ADR (NASDAQ: IPHA ) Rapt Therapeutics Inc (NASDAQ: RAPT ) (went public Oct. 31) Viela Bio Inc (NASDAQ: VIE ) (went public Oct. 3) XOMA Corp (NASDAQ: XOMA ) Down In The Dumps (Biotech stocks that hit 52-week lows Nov. 7.) Allena Pharmaceuticals Inc (NASDAQ: ALNA ) (reported positive results from two studies evaluating its reloxaliase in high-risk patients with enteric hyperoxaluria and advanced chronic kidney disease) Auris Medical Holding Ltd (NASDAQ: EARS ) bluebird bio Inc (NASDAQ: BLUE ) Caladrius Biosciences Inc (NASDAQ: CLBS ) (reacted to its third-quarter results) CENTOGENE ORD (NASDAQ: CNTG ) (went public Thursday) Cocrystal Pharma Inc (NASDAQ: COCP ) Corbus Pharmaceuticals Holdings Inc (NASDAQ: CRBP ) Helius Medical Technologies Inc (NASDAQ: HSDT ) Infinity Pharmaceuticals Inc.
   Collegium Pharmaceutical (COLL) Q2 Earnings Surpass Estimates  2019/08/07 22:35:06 Zacks Investment Research
Collegium Pharmaceutical (COLL) delivered earnings and revenue surprises of 152.63% and -1.31%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
   Earnings Preview: Collegium Pharmaceutical (COLL) Q2 Earnings Expected to Decline  2019/07/31 14:36:33 Zacks Investment Research
Collegium Pharmaceutical (COLL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

 関連キーワード  (医薬品 米国株 コレギウム・ファ―マシュ―ティカル COLL Collegium Pharmaceutical Inc.)

 twitter  (公式ツイッターやCEOツイッターなど)